Dr Jamy Highlights HMAs Plus Venetoclax for Patients With R/R AML
Recommended
Dr Jamy Highlights HMAs Plus Venetoclax for Patients With R/R AML
Omer Hassan Jamy, MD, Assistant Professor, University of Alabama at Birmingham, highlights a retrospective study on hypomethylating agents (HMAs) plus venetoclax versus intensive chemotherapy for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->